Alessandra Tedeschi

Statistics

Publications

155

Citations

11.6K

H-Index

Active since

1987

Affiliations

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda(Current)

Istituti di Ricovero e Cura a Carattere Scientifico

Vita-Salute San Raffaele University

Peter MacCallum Cancer Centre

Monash University

Alessandra Tedeschi is an author at Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda specializing in medicine, oncology, and hematologic malignancy therapy.

ORCID

Publications per year

1987–2025

155

Publications

155

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

Jan A. Burger, Alessandra Tedeschi, Paul M. Barr et al. · New England Journal of Medicine · 2015 · 1.6K citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

Carol Moreno, Richard Greil, Fatih Demırkan et al. · The Lancet Oncology · 2018 · 548 citations

Medicine, Oncology, Pharmacology +13

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

Jan A. Burger, Paul M. Barr, Tadeusz Robak et al. · Leukemia · 2019 · 463 citations · Full text

Medicine, Oncology, Pharmacology +16

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Constantine S. Tam, Stephen Opat, Shirley D’Sa et al. · Blood · 2020 · 448 citations · Full text

Medicine, Hematology, Pharmacology +4

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

Constantine S. Tam, Judith Trotman, Stephen Opat et al. · Blood · 2019 · 367 citations · Full text

Medicine, Oncology, Pharmacology +10

1–5 of 155